Company profile
ALECTOR, INC.
NASDAQ:ALECBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LATOZINEMAB | phase1_2 | — | 8 | active |
| OSUGACESTAT | phase1 | — | 4 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03636204 | phase1 | completed | 2018-09-14 | 2019-12-31 | Alector Inc. | A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation |
| NCT05744401 | phase2 | terminated | 2023-01-04 | 2025-01-31 | Alector Inc. | A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease |
| NCT04111666 | phase1 | completed | 2019-12-14 | 2022-06-09 | Alector Inc. | A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 |
| NCT05053035 | phase2 | terminated | 2021-09-02 | 2022-10-28 | Alector Inc. | A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS |
| NCT04592874 | phase2 | completed | 2021-01-22 | 2024-08-19 | Alector Inc. | A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease |
FDA applications (0)
No records yet.